… Recurrent cancer was noted in 40 patients, four while receiving erlotinib treatment and 36
after stopping erlotinib (Appendix Table A1, online only). The median time to recurrence after …

… approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and
Pancreatic Cancer. Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor …

… to be maintained on erlotinib treatment at the lowest dose that keeps them in remission, as
long as no considerable adverse effects are observed. Treatment resistance, as observed in …

… vascular endothelial growth factor pathways are … growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) resistance. We hypothesized that treatment with cabozantinib plus erlotinib …

… Our study showed that, compared with patients with EGFR exon 19 deletion, patients with
exon 21 mutation had prolonged PFS after erlotinib treatment, suggesting erlotinib combined …

… during treatment with anticancer epidermal growth factor … skin and propose new treatments
or preventative measures. … of erlotinib-induced dry skin and to propose new treatment …

… , erlotinib and afatinib are approved for first‐line treatment of … ) bearing an activating
epidermal growth factor receptor (EGFR) … treatment with gefitinib, erlotinib or afatinib, for first‐line …

… This study included 599 patients with EGFR-mutant NSCLC who started first-line gefitinib,
erlotinib, afatinib treatment for advanced NSCLC at Samsung Medical Center between …

… In addition, erlotinib treatment had no obvious diminish effect on the NGF-induced EMT
process in both NC- and TrkA-knockdown cells. We then further examined the influence of TrkA …

… Screening for epidermal growth factor receptor mutations in lung cancer. … combination of
erlotinib and bevacizumab superior to erlotinib alone to treat epidermal growth factor receptor (…